NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
神經博製藥和其他兩隻低價股票的內部人員正在購買
The Dow Jones index closed lower by around 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道瓊斯指數週二收盤下跌約300點。當內部人士購買或出售股票時，這表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以將此視爲他們整體投資或交易決策的一個因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是細價股最近幾筆值得注意的內幕交易。欲了解更多信息，請訪問Benzinga的內幕交易平台。
Nanophase Technologies
納米相技術
- The Trade: Nanophase Technologies Corporation (NASDAQ:NANX) Chief Operating Officer Kevin Cureton bought a total of 11,675 shares at an average price of $1.49. To acquire these shares, it cost around $17,414.
- What's Happening: On April 23, Nanophase Technologies announced financial results for the first quarter ended March 31, 2024.
- What Nanophase Technologies Does: Nanophase Technologies Corp is engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.
- 交易：Nanophase Technologies Corporation（納斯達克股票代碼：NANX）首席運營官凱文·庫雷頓以1.49美元的平均價格共購買了11,675股股票。收購這些股票的成本約爲17,414美元。
- 發生了什麼：4月23日，Nanophase Technologies公佈了截至2024年3月31日的第一季度財務業績。
- Nanophase Technologies做什麼：Nanophase Technologies Corp從事工程納米材料解決方案和更大的亞微米材料的生產，例如個人護理防曬霜、建築塗料、工業塗料應用以及耐磨添加劑、塑料添加劑、醫療診斷、能源。
Nuvation Bio
Nuvation Bio
- The Trade: Nuvation Bio Inc. (NYSE:NUVB) Director Xiangmin Cui acquired a total of 500,000 shares at an average price of $2.98. To acquire these shares, it cost around $1.5 million.
- What's Happening: On June 3, HC Wainwright & Co. analyst Robert Burns reiterated Nuvation Bio with a Buy and maintained a price target of $8.
- What Nuvation Bio Does: Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates.
- 交易：Nuvation Bio Inc.（紐約證券交易所代碼：NUVB）董事崔向敏共收購了50萬股股票，平均價格爲2.98美元。收購這些股票的成本約爲150萬美元。
- 發生了什麼：6月3日，HC Wainwright & Co. 分析師羅伯特·伯恩斯重申了Nuvation Bio的買入，並將目標股價維持在8美元。
- Nuvation Bio做什麼：Nuvation Bio Inc是一家生物製藥公司，通過開發差異化的新型候選療法來應對腫瘤學領域未滿足的需求。
NeuroBo Pharmaceuticals
紐羅博製藥
- The Trade: NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) President and CEO Faheem Hasnain acquired a total of 2,544,530 shares at an average price of $3.13. The insider spent around $7.97 million to buy those shares.
- What's Happening: On June 25, NeuroBo Pharmaceuticals announced the closing of up to $70 million concurrent private placement and registered direct offering priced at-the-market under Nasdaq rules.
- What NeuroBo Pharmaceuticals Does: NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases.
- 交易：NeuroBo Pharmicals, Inc.（納斯達克股票代碼：NRBO）總裁兼首席執行官法希姆·哈斯南共收購了2544,530股股票，平均價格爲3.13美元。知情人士花費了約797萬美元購買了這些股票。
- 發生了什麼：6月25日，NeuroBo Pharmicals宣佈完成高達7,000萬美元的並行私募和註冊直接發行，根據納斯達克的規定在市場上定價。
- NeuroBo Pharmaceuticals做什麼：NeuroBo Pharmaceuticals Inc是一家臨床階段的生物技術公司，主要致力於開發和商業化治療心臟代謝疾病的新藥物。
Read More: Top 3 Materials Stocks That May Explode In Q2
閱讀更多：第二季度可能爆發的三大材料股